 |
Photo = Celltrion |
[Alpha Biz= Kim Jisun] Celltrion announced on April 14 that its record-setting share cancellation—worth approximately KRW 1.8 trillion, the largest in Korea’s pharmaceutical and biotech industry—has been fully reflected in the stock market.
Following the completion of listing changes on April 13, a total of 9.11 million shares, equivalent to 3.94% of Celltrion’s total outstanding shares, have been permanently retired. As a result, shareholders are expected to benefit from an increase in per-share value.
The canceled shares accounted for about 74% of the company’s treasury stock holdings, valued at approximately KRW 1.78 trillion based on the previous day’s closing price. This exceeds the combined scale of share cancellations carried out in 2024 (KRW 701.3 billion) and 2025 (KRW 895.0 billion).
The move is expected to immediately improve earnings per share (EPS), as the total number of shares decreases while overall profits remain unchanged, thereby increasing value per share.
Market participants anticipate that key valuation metrics such as the price-to-earnings ratio (PER) will become more attractive, potentially supporting investor demand.
The company’s improving business performance is also reinforcing shareholder value. Celltrion reported consolidated revenue of KRW 4.16 trillion and operating profit of KRW 1.17 trillion last year, with operating profit surging 137.5% year-on-year. For this year, the company is targeting revenue of approximately KRW 5.3 trillion and operating profit of around KRW 1.8 trillion.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
